 Immutep Limited NASDAQ: IMMP has announced a new collaboration and supply agreement with Germany-based Merck KGaA OTC: MKGAF for a Phase 12a INSIGHT-005 trial in patients with solid tumors. The trial will evaluate the feasibility, safety, and efficacy of Immuteps lead product candidate, eftilagimod alpha efti or IMP321, in combination with bintrafusp alfa M7824. 